The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group Women diagnosed with O/PC/FT ...

Plasma Micro-RNA 371 Expression in Early-Stage Germ Cell Tumors: Are We Ready to Move Toward Biology-Based Decision Making? The following represents disclosure information provided by authors of this ...

Eprenetapopt in the Post-Transplant Setting: Mechanisms and Future Directions ...

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 Patients (n = 1,013) with EGFR/ALK ...

Authors retain all rights in any data supplements associated with their articles. The ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of ...

This double-blind phase III trial randomly assigned patients with newly diagnosed advanced ovarian cancer and a BRCA mutation in clinical response to platinum-based chemotherapy to maintenance ...

Positron Emission Tomography–Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance) Zanubrutinib is a potent, irreversible next-generation Bruton tyrosine kinase (BTK) ...

View all available purchase options and get full access to this article.

Purpose To provide evidence-based recommendations to practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2) –positive advanced breast ...

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 Clinical trials frequently include ...

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial PREMMplus (score ≥ 2.5%) had 93.9%, 91.7%, and 89.3% ...